"Lung Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the LUNG.
Descriptor ID |
D008175
|
MeSH Number(s) |
C04.588.894.797.520 C08.381.540 C08.785.520
|
Concept/Terms |
Lung Neoplasms- Lung Neoplasms
- Pulmonary Neoplasms
- Neoplasms, Lung
- Lung Neoplasm
- Neoplasm, Lung
- Neoplasms, Pulmonary
- Neoplasm, Pulmonary
- Pulmonary Neoplasm
Lung Cancer- Lung Cancer
- Cancer, Lung
- Cancers, Lung
- Lung Cancers
- Pulmonary Cancer
- Cancer, Pulmonary
- Cancers, Pulmonary
- Pulmonary Cancers
- Cancer of the Lung
- Cancer of Lung
|
Below are MeSH descriptors whose meaning is more general than "Lung Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Lung Neoplasms".
This graph shows the total number of publications written about "Lung Neoplasms" by people in this website by year, and whether "Lung Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 13 | 1 | 14 |
1995 | 10 | 1 | 11 |
1996 | 12 | 4 | 16 |
1997 | 12 | 0 | 12 |
1998 | 6 | 3 | 9 |
1999 | 7 | 6 | 13 |
2000 | 11 | 1 | 12 |
2001 | 8 | 2 | 10 |
2002 | 15 | 3 | 18 |
2003 | 11 | 3 | 14 |
2004 | 10 | 0 | 10 |
2005 | 16 | 0 | 16 |
2006 | 13 | 0 | 13 |
2007 | 10 | 0 | 10 |
2008 | 14 | 1 | 15 |
2009 | 21 | 1 | 22 |
2010 | 19 | 3 | 22 |
2011 | 7 | 3 | 10 |
2012 | 12 | 0 | 12 |
2013 | 9 | 1 | 10 |
2014 | 15 | 0 | 15 |
2015 | 22 | 1 | 23 |
2016 | 17 | 2 | 19 |
2017 | 12 | 2 | 14 |
2018 | 17 | 4 | 21 |
2019 | 8 | 1 | 9 |
2020 | 14 | 1 | 15 |
2021 | 11 | 0 | 11 |
2022 | 4 | 0 | 4 |
2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lung Neoplasms" by people in Profiles.
-
CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
-
The International Association for the Study of Lung Cancer Early Lung Imaging Confederation Open-Source Deep Learning and Quantitative Measurement Initiative. J Thorac Oncol. 2024 Jan; 19(1):94-105.
-
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 09; 18(9):1209-1221.
-
Emphysema Detection in the Course of Lung Cancer Screening: Optimizing a Rare Opportunity to Impact Population Health. Ann Am Thorac Soc. 2023 04; 20(4):499-503.
-
Preliminary Testing of A Web-Based Lung Cancer Screening Decision Coaching Tool for Older Chinese American Smokers and Their Providers. J Natl Med Assoc. 2023 Apr; 115(2):223-232.
-
Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
-
Development of exploratory algorithms to aid in risk of malignancy prediction of indeterminate pulmonary nodules. Clin Chim Acta. 2022 Oct 01; 535:197-202.
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 06; 6:e2100496.
-
The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
-
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. J Thorac Oncol. 2022 05; 17(5):661-674.